Use the hyperlinks, where available to access additional clinical trial information.
A placebo controlled study to compare ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome
HOVON (the Haemato Oncology Foundation for Adults in the Netherlands)
Other Non-Commercial Sponsor
Eligible patients will receive up to two cycles of induction therapy, up to three cycles of consolidation therapy and maintenance treatment. Across the three treatments, patients will be randomly selected to receive a placebo (no treatment) or oral Enasidenib or Ivosidenaib once a day for the whole induction cycle, until the end of consolidation and for up to two years maintenance.